Dyne Therapeutics, Inc. (DYN) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $16.00K; Additional Paid in CapitalUSD $2.40B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-353.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $16.00K; Additional Paid in CapitalUSD $2.38B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-137.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $16.00K; Additional Paid in CapitalUSD $2.37B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $475.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $14.00K; Additional Paid in CapitalUSD $1.98B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $496.00K.
Dyne Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $16.00K | $2.40B | $-353.00K | $-1.70B | $702.15M | 3 month · $14.98M |
| 2026-03-31 | (m) | $16.00K | $2.38B | $-137.00K | $-1.52B | $865.05M | 3 month · $13.08M |
| 2025-12-31 | $0.00 | $16.00K | $2.37B | $475.00K | $-1.40B | $972.13M | 12 month · $45.85M |
| 2025-09-30 | $0.00 | $14.00K | $1.98B | $496.00K | $-1.28B | $691.78M | 3 month · $11.08M |
| 2025-06-30 | $0.00 | $11.00K | $1.75B | $252.00K | $-1.18B | $571.45M | 3 month · $10.52M |
| 2025-03-31 | $0.00 | $11.00K | $1.73B | $241.00K | $-1.07B | $668.97M | 3 month · $13.02M |
| 2024-12-31 | $0.00 | $10.00K | $1.58B | $6.00K | $-949.93M | $629.84M | 12 month · $45.86M |
| 2024-09-30 | $0.00 | $10.00K | $1.57B | $478.00K | $-860.39M | $705.54M | 3 month · $8.74M |
| 2024-06-30 | $0.00 | $10.00K | $1.54B | $-240.00K | $-763.26M | $775.19M | 3 month · $6.74M |
| 2024-03-31 | $0.00 | $9.00K | $1.18B | $-132.00K | $-698.16M | $478.06M | 3 month · $19.91M |
| 2023-12-31 | $0.00 | $6.00K | $723.80M | $0.00 | $-632.51M | $91.29M | 12 month · $19.97M |
| 2023-09-30 | $0.00 | $6.00K | $717.92M | $-13.00K | $-565.87M | $152.04M | 3 month · $4.88M |
| 2023-06-30 | $0.00 | $6.00K | $712.59M | $-56.00K | $-505.66M | $206.88M | 3 month · $4.75M |
| 2023-03-31 | $0.00 | $6.00K | $682.89M | $-203.00K | $-440.76M | $241.94M | 3 month · $4.62M |
| 2022-12-31 | $0.00 | $6.00K | $649.50M | $-571.00K | $-396.57M | $252.36M | 12 month · $15.18M |
| 2022-09-30 | $0.00 | $6.00K | $608.47M | $-983.00K | $-357.75M | $249.74M | 3 month · $3.83M |
| 2022-06-30 | $0.00 | $6.00K | $604.57M | $-1.16M | $-316.36M | $287.06M | 3 month · $3.03M |
| 2022-03-31 | $0.00 | $6.00K | $601.44M | $-930.00K | $-264.06M | $336.46M | 3 month · $4.49M |
| 2021-12-31 | $0.00 | $6.00K | $596.93M | $-269.00K | $-228.47M | $368.20M | 12 month · $17.54M |
| 2021-09-30 | (m) | $6.00K | $590.83M | $-34.00K | $-176.69M | $414.12M | 3 month · $3.64M |
| 2021-06-30 | (m) | $6.00K | $586.74M | $-41.00K | $-134.11M | $452.60M | 3 month · $4.24M |
| 2021-03-31 | (m) | $6.00K | $582.47M | $-68.00K | $-104.15M | $478.26M | 3 month · $3.65M |
| 2020-12-31 | $0.00 | $5.00K | $421.57M | $-27.00K | $-79.18M | $342.37M | 12 month · $6.59M |
| 2020-09-30 | (m) | $5.00K | $417.37M | (m) | $-50.53M | $366.85M | 3 month · $2.23M |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-719.00K | 3 month · $75.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $8.19M | 3 month · $66.00K |
| 2019-12-31 | (m) | $1.00K | $6.35M | (m) | $-19.75M | $14.04M | 12 month · $26.00K |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $19.43M | 3 month · $7.00K |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-8.46M | 3 month · $4.00K |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-6.96M | 3 month · $2.00K |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-4.88M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |